SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 12th, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (this "Agreement") is dated as of November ___, 2012, among Oramed Pharmaceuticals Inc., a Delaware corporation (the "Company"), and the investors identified on the signature page hereto (each, an "Investor" and collectively the “Investors”).
CLINICAL TRIAL AGREEMENTClinical Trial Agreement • December 12th, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
This Agreement is entered into as of September 11, 2011 by and between HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LIMITED, a company duly incorporated under the laws of Israel, of P.O. Box 12000, Jerusalem 91120, (hereinafter: “Hadasit” or the “Institution”) and Dr. Daniel Schurr and Dr. Miriam Kidron (the ”Investigator”) on one hand and Oramed Ltd., a corporation organized under the laws of the state of Delaware, with its registered office located at 2/5 Hi-Tech Park Givat-Ram P.O. Box 39098, Jerusalem 91390, (hereinafter: “Sponsor”), on the other hand.
ContractMaster Services Agreement • December 12th, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations • New York
This Master Services Agreement (the “Agreement”), dated as of 27 September, 2012 (the “Effective Date”), is between Medpace, Inc., an Ohio Corporation with a principal place of business at 5375 Medpace Way, Cincinnati, OH 45227 (“MEDPACE”) and Oramed, Ltd., a company established pursuant to the laws of the State of Israel, with a principal place of business at Hi-Tech Park 2/5 Givat Ram, PO Box 39098, Jerusalem, 91390, Israel, (“SPONSOR”). MEDPACE and SPONSOR are sometimes referred to herein individually as a “Party” and together as the “Parties”.
Amendment to Consultant Service Agreement Dated April 21, 2009 Between Oramed (Company) and ADRES (Contractor)Consultant Service Agreement • December 12th, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
According to the original agreement dated April 21, 2009, the last milestone payment of 71,000 US$ was due on IND submission. Because of delays in the product development resulted in delay in IND submission, the following changes to the original agreement are introduced as agreed by the parties:
COMMON STOCK PURCHASE WARRANT To Purchase ____________ Shares of Common Stock of ORAMED PHARMACEUTICALS INC.Security Agreement • December 12th, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ______________________ (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the fifth anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Oramed Pharmaceuticals Inc. a Delaware corporation (the “Company”), up to ____________ shares (the “Warrant Shares”) of Common Stock, par value $0.001 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
CONFIDENTIAL PORTIONS HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”).** TASK ORDER MEDPACE Task Order Number: 1 MEDPACE Project Number:...Task Order • December 12th, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
WHEREAS, MEDPACE and SPONSOR have entered into that certain Master Services Agreement dated 27 September 2012 (the “Master Services Agreement”); and
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 12th, 2012 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (this "Agreement") is dated as of October 30, 2012, among Oramed Pharmaceuticals Inc., a Delaware corporation (the "Company"), and D.N.A Biomedical Solutions Ltd., an Israeli company (referred to herein as "D.N.A" or an "Investor").
